The main aim of the study is to examine whether the effects of intranasal oxytocin on eye-gaze behavior towards social stimuli are modulated via individual differences in trait autism
In this double-blind, within subject, placebo controlled design a total of n = 40 healthy male subjects will receive either 24 IU of oxytocin or placebo (interval between administration \> two weeks). 45 minutes after treatment subjects will undergo a total of 7 eye-tracking paradigms examining eye-gaze behavior during social processing: (1) dynamic social-nonsocial visual preference task during which movies of dynamic geometric images (DGI) and dynamic social images (DSI) will be presented; (2) non-biological versus biological motion task; (3) social attention and motivation of sharing enjoyment; (4) preference for emotional faces versus schematic faces (emoticons); (5) shared social attention - shared gaze direction with an actor shifting his attention to different objects; (6) preferred visual scanning of face regions in emotional faces; and, (7) eye gaze in response to empathy eliciting visual stimuli. Autistic and associated traits will be assessed using the Autism Spectrum Quotient (ASQ), Social Responsibilities Scale (SRS) and the Interpersonal Reactivity Index (IRI). Within-subject differences in the effects of oxytocin on social eye gazing behaviour will be related to individual differences in autistic traits.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
40
24 IU of oxytocin nasal spray will be applied to each subject.
24 IU of of placebo nasal spray will be applied to each subject.
school of life science and technology, University of Electronic Science and Technology of China
Chengdu, Sichuan, China
RECRUITINGUniversity of Electronic Science and Technology of China
Chengdu, Sichuan, China
RECRUITINGGlobal eye gaze characteristic: differences between oxytocin and placebo treatment
Global eye-gaze patterns will be compared between the administration of oxytocin and placebo
Time frame: 45-90 minutes after treatment administration
Feature-specific eye gaze characteristics: differences between oxytocin and placebo treatment
Localized feature-specific eye gaze patterns will be compared between oxytocin and placebo treatment
Time frame: 45-90 minutes after treatment administration
Global eye gaze characteristic - associations with autism traits
Within-subject differences in global eye gaze characteristics between the oxytocin and placebo administration will be examined for associations with individual differences in autism traits
Time frame: 45-90 minutes after treatment administration
Feature-specific eye gaze characteristics - associations with trait autism
Within-subject differences in localized feature-specific eye gaze characteristics between the oxytocin and placebo administration will be examined for associations with individual differences in autism traits
Time frame: 45-90 minutes after treatment administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.